Management of hepatitis B reactivation in patients receiving cancer chemotherapy

被引：26
作者：
Huang, Yi-Wen [2 ,3 ,4 ,5 ]
Chung, Raymond T. [1 ]
机构：
[1] Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Boston, MA 02114 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA USA
[3] Cathay Gen Hosp, Med Ctr, Ctr Liver, Taipei, Taiwan
[4] Taipei Med Univ, Sch Med, Taipei, Taiwan
[5] Natl Taiwan Univ Coll Med & Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2012年 / 5卷 / 05期
关键词：
cancer; chemotherapy; HBV reactivation; hepatitis B virus; lamivudine; prophylaxis; VIRUS HBV REACTIVATION; NON-HODGKINS-LYMPHOMA; CYTOTOXIC CHEMOTHERAPY; BREAST-CANCER; PROPHYLACTIC LAMIVUDINE; PREEMPTIVE LAMIVUDINE; HEPATOCELLULAR-CARCINOMA; HEMATOLOGIC MALIGNANCIES; LIVER-TRANSPLANTATION; POSITIVE PATIENTS;
D O I：
10.1177/1756283X12450245
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.
引用
收藏
页码：359 / 370
页数：12
相关论文
共 84 条
[11]  
Dai MS, 2001, CANCER-AM CANCER SOC, V92, P2927, DOI 10.1002/1097-0142(20011201)92:11<2927::AID-CNCR10109>3.0.CO
[12]  
2-W
[13]   Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors [J].
Day, Fiona L. ;
Karnon, Jonathan ;
Rischin, Danny .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3270-3277
[14]   Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: A preliminary report [J].
El-Sayed, MH ;
Shanab, G ;
Karim, AM ;
El-Tawil, A ;
Black, A ;
Dixon, JS .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2004, 21 (02) :145-156
[15]  
GALBRAITH RM, 1975, LANCET, V2, P528
[16]   Reactivation of Hepatitis B [J].
Hoofnagle, Jay H. .
HEPATOLOGY, 2009, 49 (05) :S156-S165
[17]  
Hsu C., 2006, GASTROENTEROLOGY, V131, pS297
[18]   A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial [J].
Hsu, Chiun ;
Hsiung, Chao A. ;
Su, Lh-Jen ;
Hwang, Wei-Shou ;
Wang, Ming-Chung ;
Lin, Sheng-Fung ;
Lin, Tseng-Hsi ;
Hsiao, Hui-Hua ;
Young, Ji-Hsiung ;
Chang, Ming-Chih ;
Liao, Yu-Min ;
Li, Chi-Cheng ;
Wu, Hung-Bo ;
Tien, Hwei-Fang ;
Chao, Tsu-Yi ;
Hu, Tsang-Wu ;
Cheng, Ann-Lii ;
Chen, Pei-Jer .
HEPATOLOGY, 2008, 47 (03) :844-853
[19]  
Hui CK, 2006, GASTROENTEROLOGY, V131, P59, DOI 10.1053/j.gastro.2006.04.015
[20]   Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy [J].
Hui, CK ;
Cheung, WWW ;
Au, WY ;
Lie, AKW ;
Zhang, HY ;
Yueng, YH ;
Wong, BCY ;
Leung, N ;
Kwong, YL ;
Liang, R ;
Lau, GKK .
GUT, 2005, 54 (11) :1597-1603
123456789